Lilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bn
Next issueIssue 16 · Tue 29 Sep 

Companies

Transcend

Transcend Therapeutics, Inc.

HQ
United States
Status
acquired
Listing
Private

otsuka.co.jpregistryverified 2026-09-25

Notes on the record

Target in D005-otsuka-transcend-2026. Added 2026-09-25 so the deal tape can print its short name. Sourced to the Otsuka completion release; TDnet and EDINET not checked, as the deal row records.

Assets

No asset in data/assets.csv names this company as owner.

Registered trials

No row in data/trials.csv resolves to this company's assets.

Deals

In the briefing

No published issue carries the TRANSCEND tag.